Home
ARQT
ARQT News

Latest Arcutis Biotherapeutics Inc. (ARQT) News on May 31, 2025

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

GlobeNewswire

a day ago

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

MT Newswires

8 days ago

Arcutis Biotherapeutics' Foam Psoriasis Treatment Gets FDA Approval

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

GlobeNewswire

8 days ago

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

GlobeNewswire

16 days ago

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements

TipRanks

23 days ago

Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements

Arcutis Biotherapeutics First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.

23 days ago

Arcutis Biotherapeutics First Quarter 2025 Earnings: Beats Expectations

Thomson Reuters StreetEvents

24 days ago

Q1 2025 Arcutis Biotherapeutics Inc Earnings Call

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

GlobeNewswire

24 days ago

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com

24 days ago

Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates

Zacks

24 days ago

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

24 days ago

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

Exploring High Growth Tech Stocks In The US Market

Simply Wall St.

25 days ago

Exploring High Growth Tech Stocks In The US Market

What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings

GuruFocus.com

a month ago

What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a month ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth

Zacks

a month ago

Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth

Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

a month ago

Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

Zacks

a month ago

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

GlobeNewswire

a month ago

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

MT Newswires

2 months ago

Arcutis Biotherapeutics Names New Chief Financial Officer

Arcutis Announces Chief Financial Officer Transition

GlobeNewswire

2 months ago

Arcutis Announces Chief Financial Officer Transition

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last?

Zacks

2 months ago

Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last?

Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday?

Insider Monkey

2 months ago

Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday?

MT Newswires

2 months ago

Sector Update: Health Care Stocks Advance in Late Afternoon Trading

MT Newswires

2 months ago

Arcutis Agrees to Stay Patent Lawsuit Against Padagis

Arcutis and Padagis Agree to Stay Patent Lawsuit

GlobeNewswire

2 months ago

Arcutis and Padagis Agree to Stay Patent Lawsuit

Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone

Investor's Business Daily

2 months ago

Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone

How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85%

Zacks

2 months ago

How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85%

Are Medical Stocks Lagging Cardinal Health (CAH) This Year?

Zacks

2 months ago

Are Medical Stocks Lagging Cardinal Health (CAH) This Year?

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire

2 months ago

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

Exploring 3 High Growth Tech Stocks in the US Market

Simply Wall St.

2 months ago

Exploring 3 High Growth Tech Stocks in the US Market

MT Newswires

2 months ago

Arcutis Biotherapeutics Unit Gets Health Canada Approval for Atopic Dermatitis Treatment

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age

CNW Group

2 months ago

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

Zacks

3 months ago

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

GlobeNewswire

3 months ago

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average

Zacks

3 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?

Zacks

3 months ago

Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

GlobeNewswire

3 months ago

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Simply Wall St.

3 months ago

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Arcutis Biotherapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

3 months ago

Arcutis Biotherapeutics Full Year 2024 Earnings: Beats Expectations

MT Newswires

3 months ago

Arcutis Biotherapeutics Says FDA Accepts Supplemental New Drug Application for Zoryve Cream

U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

GlobeNewswire

3 months ago

U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

MT Newswires

3 months ago

Arcutis Biotherapeutics Q4 Loss Narrows, Revenue Rises

Arcutis Biotherapeutics Inc (ARQT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

3 months ago

Arcutis Biotherapeutics Inc (ARQT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q4 Loss, Tops Revenue Estimates

Zacks

3 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q4 Loss, Tops Revenue Estimates

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire

3 months ago

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Arcutis Biotherapeutics Inc (ARQT) Q4 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

3 months ago

Arcutis Biotherapeutics Inc (ARQT) Q4 2024: Everything You Need To Know Ahead Of Earnings

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

GlobeNewswire

3 months ago

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks

3 months ago

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

3 months ago

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet

Zacks

3 months ago

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet

High Growth Tech Stocks To Watch In February 2025

Simply Wall St.

3 months ago

High Growth Tech Stocks To Watch In February 2025

Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

Zacks

4 months ago

Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?

Zacks

4 months ago

Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?

Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher

Zacks

4 months ago

Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.

Investor's Business Daily

4 months ago

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"

PR Newswire

4 months ago

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"

Are Medical Stocks Lagging Addus HomeCare (ADUS) This Year?

Zacks

4 months ago

Are Medical Stocks Lagging Addus HomeCare (ADUS) This Year?

Arcutis to Present at the Guggenheim SMID Cap Biotech Conference

GlobeNewswire

4 months ago

Arcutis to Present at the Guggenheim SMID Cap Biotech Conference

Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade

Zacks

4 months ago

Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade

MT Newswires

5 months ago

Arcutis Biotherapeutics Expects Fiscal Q4 Revenue to Soar Driven by Zoryve Demand

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

GlobeNewswire

5 months ago

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

High Growth Tech Stocks In The United States To Watch

Simply Wall St.

5 months ago

High Growth Tech Stocks In The United States To Watch

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

Zacks

5 months ago

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

MT Newswires

5 months ago

HC Wainwright Initiates Arcutis Biotherapeutics at Buy With $19 Price Target

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Zacks

5 months ago

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

MT Newswires

5 months ago

Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA for Zoryve Cream

Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

GlobeNewswire

5 months ago

Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks To Watch In December 2024

Simply Wall St.

6 months ago

High Growth Tech Stocks To Watch In December 2024

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 12/04/2024

Arcutis Announces Promotions on Executive Management Team

GlobeNewswire

6 months ago

Arcutis Announces Promotions on Executive Management Team

Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect?

Zacks

6 months ago

Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect?

Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy?

Zacks

6 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy?

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average

Zacks

6 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average

Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors

Zacks

6 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors

Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now

Zacks

6 months ago

Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average

Zacks

6 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

GlobeNewswire

7 months ago

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?

Zacks

7 months ago

Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?

Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

7 months ago

Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations

Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ...

GuruFocus.com

7 months ago

Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ...

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates

Zacks

7 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

7 months ago

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

High Growth Tech Stocks In The United States To Watch

Simply Wall St.

7 months ago

High Growth Tech Stocks In The United States To Watch

Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result

GuruFocus.com

7 months ago

Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

7 months ago

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Zacks

7 months ago

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

GlobeNewswire

7 months ago

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

GlobeNewswire

7 months ago

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

MT Newswires

7 months ago

Arcutis Biotherapeutics' Zoryve Approved to Treat Seborrheic Dermatitis in Canada

Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis

Pharmaceutical Technology

7 months ago

Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis

Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

CNW Group

7 months ago

Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

MT Newswires

7 months ago

Arcutis Biotherapeutics Receives Approval in Canada for Skin Disease Cream Zoryve

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

GlobeNewswire

7 months ago

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments

Insider Monkey

8 months ago

Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments

Share on Social Networks: